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High density lipoprotein cholesterol (HDL-C) is a modifiable risk factor in cardiovascular disease and 
devices suitable for its determination at the point of care are critical to the future management of 
hypercholesterolaemia. An electrochemical biosensor for measuring HDL-C was developed. The 10 
biosensor was based on a homogeneous assay methodology for selective determination of HDL-C in 
combination with a printed electrochemical sensor for measuring the reduction of hydrogen peroxide at a 
silver paste electrode. The polyoxyethylene alkylene tribenzylphenyl ether surfactant (Emulgen B-66) 
was found to be capable of both the selective dissolution of HDL particles, as well as the enhanced 
electrocatalytic reduction of hydrogen peroxide. The resulting biosensor was shown to have a linear 15 
response to HDL-C from 0.5 to 4 mM (r2=0.998) with an average r.s.d. of 7%. The biosensor was also 
used to analyse HDL-C in thirteen serum samples and had good agreement with a commercial 
spectrophotometric precipitation-based assay (r=0.7222; p < 0.058). 
Introduction  
Cholesterol levels, including high density lipoprotein cholesterol 20 
(HDL-C) are modifiable risk factors for cardiovascular disease 
(CVD), a condition which remains the number one global cause 
of death.1-3 Levels of HDL-C above 60 mg/dL (1.55 mM) are 
considered to have a positive protective role in heart disease, 
while low HDL-C levels (less than 40 mg/dL or about 1 mM) are 25 
linked to an increase in heart attack risk. For this reason, the 
importance of  measurement of HDL-C has been emphasized by 
the National Cholesterol Education Programme (NCEP) since the 
late 1980s. 4, 5 The measurement of HDL-C is also important for 
two other purposes: 1, 6, 7 30 
1. The calculation of (low density lipoprotein cholesterol) 
LDL-C using the Friedewald formula: LDL-C = Total 
cholesterol (TC) - (HDL-C + TG/5) 
2. The calculation of non-HDL cholesterol, determined by 
subtracting the HDL cholesterol concentration from the 35 
TC content. Non-HDL-C has been recommended as a 
target for preliminary CVD prevention.  
The gold standard for measurement of HDL-C and other 
cholesterols is the method developed by the Centres for Disease 
Control and Prevention (CDC).7 This method is highly complex 40 
and requires 5.0 mL of sample which is subjected to 
ultracentrifugation, precipitation and measurement using the 
Abell-Kendall method. Since there are only a few laboratories 
capable of performing the ultracentrifugation steps necessary in 
the CDC method, the Cholesterol Reference Method Laboratory 45 
Network (CRMLN) developed a simpler method based on a 
modified dextran sulphate procedure.8 However, this technique, 
like the CDC method, also required large sample volumes and 
also required multiple manual processing steps including the 
removal of triglycerides which still renders this method 50 
unsuitable in most clinical laboratories and in automated 
analysers.9, 10  
 
In the past three decades, chemical precipitation methods, and 
more recently, homogeneous assays have been used to measure 55 
serum HDL-C in clinical laboratories. Homogeneous assays were 
a major step forward in improving the precision of earlier 
precipitation methods. Full automation eliminated manual 
pipetting, off-line pre-treatment, centrifugation and separation 
steps and improved assay precision, in line with recommended 60 
NCEP criteria. To date, there are several commercial colorimetric 
assays available for the quantitative measurement of HDL-C in 
serum.3, 11 All of these determine the amount of H2O2 produced 
from the enzymatic reaction of cholesterol present in HDL, to 
cholest-4-en-3-one, which can then be measured 65 
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spectrophotometrically.  
Homogeneous assay methodologies have been developed which 
allow the direct and selective analysis of HDL-C in a single step.3 
In one method, a polyoxyethylene alkylene tribenzylphenyl ether 
surfactant (Emulgen B-66) was found to be capable of the 5 
selective solubilisation of HDL-C, allowing the enzymatic 
reaction of HDL-C to H2O2 as follows:  
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where ChEs is cholesterol esterase and ChOx is cholesterol 
oxidase. However, such assays are only appropriate for laboratory 
analyses. The movement of many routine blood tests away from 
the central laboratory to the point-of-care is a major trend in 
healthcare provision. A point of care device that measures HDL-15 
C directly is very attractive in biomedical diagnostics and would 
be highly advantageous in the self-management of 
hypercholesterolemia.12-14 Electrochemical techniques lend 
themselves well to the fabrication of low cost, point of care and 
disposable diagnostic devices. Thus, it would seem a common 20 
sense approach to develop electrochemical biosensor 
methodologies that are capable of measuring HDL-C using a 
similar principle, with the measurement of H2O2 performed 
electrochemically.15, 16 While a number of electrochemical 
biosensors for cholesterol have been developed,17-20, 20-30 to date, 25 
there are just a few published examples of electrochemical 
biosensors for HDL-C.31, 32 Kinoshita et al., developed an 
amperometric sensor based on a homogeneous assay in which, a 
peroxidase-entrapped and ferrocene-embeded carbon paste 
electrode was used to measure the H2O2 produced after enzymatic 30 
reaction of HDL-C. PEG-modified enzymes in the presence of -
cyclodextrin sulphate and MgCl2 were employed to impart 
selectivity to the measurement of HDL-C. This method was 
performed at 37°C and was only linear up to 0.04 mM. However, 
since it is important to measure HDL-C directly up to at least 2 35 
mM preferentially at room temperature, their method would be 
unsuitable for the development of a point of care device. Foster et 
al, developed an electrochemical device for HDL-C based on a 
precipitation methodology in which phosphotungstic acid (PTA) 
and MgCl2 were employed as the precipitation reagents.
32 40 
However, incorporation of this method on a disposable platform 
has also proved challenging. 
 
In the present work, an electrochemical sensor capable of the 
reduction of H2O2 at a modified screen-printed silver electrode 45 
was employed as the basis of a biosensor to perform the selective 
measurement of HDL-C. It has been shown previously that these 
electrodes, modified with lyotropic layers composed of surfactant 
and salt, exhibit the significantly enhanced electrocatalytic 
reduction of H2O2.
15, 16 This behaviour was exhibited for a broad 50 
range of surfactants including anionic, cationic and neutral types. 
Here, we demonstrate that the polyoxyethylene alkylene 
tribenzylphenyl ether surfactant Emulgen B-66, facilitates both 
the selective measurement of HDL-C in serum, as well as 
enhancing the electrocatalytic reduction of the H2O2 at the 55 
electrode when formed following the enzymatic catalysis of 
cholesterol esters and cholesterol with ChEs and ChOx, 
respectively. This resulted in a biosensor capable of the direct, 
room temperature measurement of HDL-C in the diagnostically 
relevant range of 0 to 4 mM.  60 
Experimental  
Materials 
Dodecylbenzenesulphonic acid (DBSA-D0989) was purchased 
from TCI Europe. Polyoxyethylene octyl phenyl ether (Triton X-
100), sodium chloride (NaCl), potassium chloride (KCl), 65 
potassium dihydrogen phosphate (KH2PO4), disodium hydrogen 
phosphate (Na2HPO), N,N-dimethyl-m-toluidine and 4-
aminoantipyrine (4-AAP) were purchased from Sigma-Aldrich 
(UK). 4-Aminoantipyrine HCl was from BDH (Dorset, UK). 
Cholesterol oxidase (O5F; 19.4 U/mg), cholesterol esterase 70 
(CE4F; 144 U/mg) and horseradish peroxidise (HRP, HRP4C; 
295 U/mg) were purchased from BBI Enzymes (Gwent, UK). 
HDL-C and LDL-C isolated from human sera and dilipidated 
difibrinated serum (S139) were purchased from Scipac Ltd. 
(Kent, UK). 30% (v/v) hydrogen peroxide solution was purchased 75 
from Merck (Nottingham, UK). Polyoxyethylene alkylene 
tribenzylphenyl ether (Emulgen B-66) was kindly donated by 
Kao Corporation (Japan). The HDL and LDL/VLDL cholesterol 
assay kit was purchased from Abcam (Cambridge, UK). Silver 
(PF-410), carbon (Electrodag 6017SS), and Ag/AgCl (Electrodag 80 
6038SS) screen printing inks were from Henkel (Netherlands). 
Methods 
Assay optimisation 
The optimisation of the concentration of Emulgen B-66 required 
for the selective determination of HDL-C over LDL-C was 85 
performed spectrophotometrically. Solutions of either 0.5 mM 
HDL-C or LDL-C in PBS were mixed with Triton X-100 or 
Emulgen B-66 in a microtitre plate with an assay mixture 
containing 39 U/mL ChEs, 23 U/mL ChOx, 0.075 % (w/v) 4-
AAP, 14 U/mL HRP and 0.06 % (v/v) N,N-dimethyl-m-toluidine. 90 
The resulting absorbance was measured at 545 nm  on a 
FLUOstar Optima plate reader (BMG Labtech, UK) with Optima 
software (version: 2.1) after incubation for three min. at room 
temperature. 
 95 
Biosensor development 
All electrochemical experiments were performed on a 3 x 3 mm 
screen printed silver paste electrode (SPE) with a Ag/AgCl screen 
printed reference electrode and carbon counter electrode. 
Electrodes were used in either an open stirred batch system in 4 100 
mL 0.1 M PBS pH 6.8 or in a low volume thin layer cell of 8 µL 
formed from a lid and 25 µm spacer layer and referred to in the 
text as ‘encapsulated’ electrodes. All electrochemical 
measurements were carried out using a PGSTAT128N 
potentiostat with NOVA 1.6 software (Metrohm, UK). Electrodes 105 
were either used without further modification or modified with an 
inkjet-printed layer of DBSA/KCl as previously reported.15 Inkjet 
printing was performed using a Dimatix Materials Printer DMP-
2831 with Dimatix Drop manager DMP-2800 series software 
(Fujifilm Dimatix, Inc., US). The effect of a number of reagents 110 
on the electrocatalytic reduction of H2O2 at the electrodes was 
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assessed in the presence of a range of assay reagents including 
6% (v/v) Emulgen B-66, ChEs (39 U/mL), ChOx (23 U/mL) and 
HDL-C (1.5 mM) in serum, either individually or in combination. 
Measurement of HDL-C in serum was performed via the 
chronoamperometric measurement of the H2O2 produced after 5 
reaction of the HDL-C with ChEs (39 U/mL) and ChOx (23 
U/mL) in 6% Emulgen B-66 at -0.1 V vs Ag/AgCl at 420 s  
following 180 s incubation at room temperature. 
Results and discussion 
Optimisation of sensor selectivity using Emulgen B-66 10 
The polyoxyethylene alkylene tribenzylphenyl ether, Emulgen B-
66 possesses a hydrophile-lipophile balance of 13.2 which is 
believed to result in the selective break down of HDL particles – 
as opposed to other lipoproteins such as LDL, (very low density 
cholesterol) VLDL and chylomicrons – thus allowing the 15 
selective enzymatic catalysis of HDL-bound cholesterols.33-35 The 
exact mechanism of HDL solubilisation remains unclear. 
However, since apolipoprotein A-I is the major apolipoprotein in 
HDL, this surfactant may solubilize the polar lipids via a specific 
interaction with this apolipoprotein.35To assess the ability of 20 
Emulgen B-66 to achieve the selective break down of HDL, the 
recovery of cholesterol from serum samples containing HDL-C or 
LDL-C was measured spectrophotometrically.  
 
Fig. 1(a) shows the percentage recovery of 0.5 mM LDL-C in 25 
serum in the presence of different concentrations of Emulgen B-
66 relative to 0.5% (v/v) Triton X-100, which is a non-specific 
surfactant and results in the release of total cholesterol (TC).36, 37 
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Fig. 1. Recovery efficiencies of (a) 0.5 mM LDL-C and (b) 0.5 mM 30 
HDL-C in serum to Emulgen B-66, relative to 0.5% (v/v) Triton X-100. 
Recovery in Triton X-100 was taken as 100%. 
In this case, recovery of LDL-C was 18±6%, 12±5% and 2.5±2% 
(v/v) for Emulgen B-66 concentrations of 1%, 2.5% and 6%, 
respectively. Conversely, the percentage recovery of 0.5 mM 35 
HDL-C in the presence of 6% Emulgen B-66 was found to be 
96±3 %, relative to 0.5% Triton X-100 (Fig. 1b).35  
 
Effect of assay reagents on the reduction of hydrogen 
peroxide 40 
In order to evaluate the electrochemical response of the electrode 
towards H2O2 in the presence of the assay components necessary 
to selectively measure HDL-C, time-based amperometric 
measurement of H2O2 was performed in the presence of 
individual or combined assay reagents. In the case of Emulgen B-45 
66, enhanced reduction currents were observed in its presence 
(Fig. 2a). In the absence of surfactant, electrodes had a response 
of 1.33×10-7 A (curve 1). However, in the presence of 6% (v/v) 
Emulgen B-66, a response of 5.98×10-6 A was obtained for 3 mM 
H2O2 (curve 3), which was a 39% current increase over that 50 
achieved for the previously reported16 combination of DBSA and 
KCl of 3.64×10-6 A (curve 2). This enhanced response might 
assist in achieving a lower limit of detection of H2O2 with the 
sensor.  
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Fig. 2. (a) Amperometric measurement of 0.5 to 3 mM H2O2 at  -0.1 V vs. 
Ag/AgCl in 4 mL stirred batch solution using: curve 1) unmodified Ag 
SPEs in 0.1 M PBS pH 6.8 solution; curve 2) DBSA/KCl modified Ag 
SPEs in 0.1 M PBS 6.8 solution; curve 3) SPEs in 6% (v/v) Emulgen B-
66 solution. (b) Cyclic voltammograms (scan rate of 0.1 V/s vs Ag/AgCl 60 
in 0.1 M PBS, pH 6.8) of: curve 1) unmodified Ag SPEs and; curve 2) 
electrodes measured after 3 h in 6% (v/v) Emulgen B-66.  
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As previously demonstrated, the electrocatalytic reduction of 
H2O2 has been shown to be significantly enhanced at a screen 
printed, silver paste electrode modified with a lytropic layer 
formed by surfactant and electrolyte.16 The mechanism for this is 
not fully understood, but may be due to several effects including 5 
a change in silver paste morphology by creating a high surface 
area nanostructure, or the formation of micellar, hexagonal or 
lamellar structures by surfactant in the solution which become 
deposited onto the silver paste and creates an enhanced surface 
for the catalytic process.16, 38 Emulgen B-66 is a nonionic 10 
surfactant which was prepared in an electrolyte solution of 0.1 M 
PBS pH 6.8. It is believed that an equivalent effect is achieved by 
this combination as has previously been demonstrated with other 
surfactant/salt combinations. However, further enhancement 
appears to result from operation of the sensor in a solution of this 15 
surfactant and electrolyte, as opposed to the modification of the 
surface alone with DBSA and KCl.16 Fig. 2(b) shows the cyclic 
voltammograms for unmodified electrodes and those in 6% 
Emulgen B-66 in PBS. These again show significant modification 
of the surface with a capacitive double layer formed by Emulgen 20 
B-66 and NaCl, as has been previously observed.  
 
The effect of the serum sample and the enzymes on the 
amperometric response of the sensor was also investigated using 
amperometry in 4 mL stirred solution. Fig. 3 shows the response 25 
of the modified sensor to H2O2 in the presence of 6% Emulgen B-
66 before, during and following exposure of the sensor to HDL-
C, ChEs and ChOx. The response of the sensor was similar 
before (a) and after (b) the combined exposure of the electrode to 
these species. However, the response was reduced significantly in 30 
the presence of HDL-C (d) and ChOx (e) alone. The presence of 
HDL or ChOx appears to significantly disrupt formation of the 
lyotropic layer on the electrode surface. In the case of HDL, it has 
already been clearly demonstrated that it interacts selectively with 
Emulgen B-66 and may disrupt the lyotropic layers formed at the 35 
electrode surface. 
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Fig. 3. Amperometric response of sensors to H2O2 (0.5 to 1.5 mM) in 
stirred solution containing 6% (v/v) Emulgen B-66: a) before exposure  
and; b) after exposure to a solution of ChEs (39 U/mL), ChOx (23 U/mL) 40 
and serum containing 1.5 mM HDL-C; c) in the presence of ChEs (39 
U/mL); d) in the presence of serum containing 1.5 mM HDL-C; e) in the 
presence of ChOx (23 U/mL). 
In the case of ChOx, it has also been found to be capable of 
disrupting phospholipid membranes via the “active site lid” 45 
mechanism.39Phospholipid membranes are also formed from the 
organisation of amphiphilic molecules and are analogous to the 
lyotropic phases formed by the interaction of Emulgen B-66 and 
electrolyte at the electrode surface. Disruption may also relate to 
the highly hydrophobic nature of the ChOx active site and the 50 
presence of additional hydrophobic domains on its surface.40 The 
sensor response was not significantly affected by the presence of 
ChEs. These results also demonstrated the reversible nature of the 
effect of both lipoprotein and ChOx on the electrocatalytic 
response of the sensor, further suggesting that only the formed 55 
lyotropic phase was affected and not the underlying electrode 
structure.  
The final response of the biosensor system to 8 µL H2O2 in a thin 
layer cell is shown in Fig. 4. This response takes into account all 
processes which either enhance the electrocatalysis such as the 60 
presence of Emulgen B-66, or which interferes with it, such as 
HDL and ChOx. Measurement was again performed at -0.1 V vs 
Ag/AgCl and the current response recorded at 420 s. The sensor 
had excellent linearity from 0 to 10 mM H2O2 (r
2=0.996, n=3), 
which makes it suitable for the direct determination of HDL-C in 65 
serum, based on a resulting one to one stoichiometric relationship 
between the concentration of cholesterol and the concentration of  
H2O2 generated, assuming full enzymatic conversion. 
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Fig. 4. Amperometric response to 8 µL of H2O2 (-0.1 V vs Ag/AgCl at 70 
420 s) in the presence of 6% (v/v) Emulgen B-66, 39 U/mL ChEs and 23 
U/mL ChOx at, (slope=3.8510-8 A/mM, r2=0.996, dotted line=95% 
confidence interval, n=3). 
 
Measurement of HDL-C 75 
The encapsulated biosensor was first applied to the measurement 
of HDL-C in dilipidated serum and sensitivity and reproducibility 
studies were performed. The chronoamperometric responses of 
the biosensor in HDL-C from 0.5 to 4 mM are shown in Fig. 5. 
Of note is the potential step chronoamperometric response 80 
occurring as the generated H2O2 is reduced at the electrode. In 
classical potential-step chronoamperometry, the signal decays to 
zero due to the total consumption of the reactant.41 Theoretically, 
the amperometric response would fall to 93% after t = L2/D, 
where L is the diffusion layer thickness (25 µm) and D is the 85 
diffusion coefficient of H2O2. Based on a value of D of 1.71 x 10
-
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5 cm2 s-1,42 this would occur after 365 ms. However, in this work, 
a pseudo steady-state response was evident after several hundred 
seconds. This is most likely due to a combination of barriers to 
diffusion slowing the process of complete reduction of the 
available H2O2
32 and the continued production of some H2O2 via 5 
the enzymatic catalysis of cholesterol. Coulometry can also be 
employed as an alternative to amperometry. The amperometric 
response taken at 420 s was found to be proportional to the HDL-
C concentration (Fig. 6). The biosensor had a linear response of 
4.4910-8 A/mM (r2 = 0.998, n=3) between 0.5 and 4 mM HDL-10 
C with an average r.s.d. of 7.0 %.  
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Fig. 5. Amperometric responses of the developed biosensor to HDL-C in 
0.1 M PBS, pH 6.8 at -0.1V (vs Ag/AgCl). Inset: Detail of response 15 
between 360 and 420 s. HDL-C concentrations: a) 0.5 mM, b) 1 mM, c) 2 
mM, d) 3 mM, e) 4 mM. 
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Fig. 6. Biosensor response to HDL-C in dilapidated serum at -0.1 V (vs 20 
Ag/AgCl). a) Assay controls using dilapidated serum in the presence of 
assay components  for 0 mM concentration and in the absence of ChEs 
and ChOx for 0.5 to 4 mM concentrations ; b) Biosensor containing 6% 
(v/v) Emulgen B-66, 39 U/mL ChEs and 23 U/mL ChOx; 
(slope=4.4910-8, r2=0.998, n=3) 25 
The measurement of HDL-C in clinical serum samples was then 
studied using the developed biosensor. The HDL-C concentration 
was also measured using a spectrophotometric precipitation assay 
methodology (Abcam, UK) and correlated against the developed 
biosensor (Fig. 7). The correlation had a slope of 0.85 with 30 
r=0.7222 (p < 0.058) for 13 samples with minimum measurement 
of two times per sample using sensor and just one time using 
assay kit due to limitations in sample availability (31 
measurements in total). The Bland–Altman plot which calculates 
the mean difference between the two methods of measurement 35 
demonstrates no bias between the two methods across the 
measured range with most of the measurements within the 95% 
confidence limit (mean difference±2Sd).43 The biosensor 
indicated slightly higher HDL-C concentrations in some 
measurements compared to the assay kit. Although the exact 40 
reason for that is not known, it may be due to varying levels of 
free cholesterol present in the samples, as this has been shown to 
affect the response of this type of assay.44 It has also been 
reported that most homogeneous assay methodologies give 
positive predictive values due to the presence of intermediate 45 
density lipoproteins (IDL) in the serum, or in the presence of high 
levels of Lp(a).45 While the biosensor was developed based on 
the homogeneous assay methodology, the Abcam assay kit is 
based on the precipitation principle.9, 10, 46, 47 Therefore, 
discrepancies between the two methods are very likely to be due 50 
to the differences in the methods and how they process and 
respond to the complex mixtures of lipids and lipoproteins in the 
sample.  
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Fig. 7. Correlation of HDL-C in clinical serum samples measured by the 55 
biosensor and the Abcam assay kit (slope= 0.85, r=0.72), Inset: Bland–
Altman plot of the difference between sensor/abcam assay kit  against the 
mean measurement of two methods in 31 measurements. (dashed lines are 
mean difference±2Sd) 
Conclusions 60 
An electrochemical biosensor was developed for the selective 
measurement of HDL-C. The sensor was able to achieve both 
selectivity and sensitivity enhancements using the surfactant 
Emulgen B-66. The presence of this surfactant was shown to 
selectively dissolve HDL over LDL. In addition, it also resulted 65 
in the enhanced electrocatalysis of H2O2 which is produced 
following the release of cholesterol ester and cholesterol from 
HDL and its catalysis by  
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ChEs and ChOx, respectively. The biosensor was shown to have 
good linearity across the diagnostically relevant range. The 
biosensor was successfully applied to the measurement of HDL-C 
in real samples, although deviation from other methods was 
observed in some of the samples which might be due to the 5 
presence of variable quantities of other lipids.  
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